Onderzoeker
Sofie Joris
- Onderzoeksexpertise:
Cancer therapy and genetics.
Familial cancer
- Trefwoorden:Geneeskunde
- Disciplines:Kankerdiagnose, Kankerpreventie, Kankertherapie
- Gebruikers van onderzoeksexpertise:
Cancer therapy and genetics.
Familial cancer
Affiliaties
- Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf19 mrt 2020 → Heden - Medische Oncologie (Departement)
Lid
Vanaf1 aug 2017 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 apr 2021 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 apr 2021 → 13 feb 2022 - Interne Geneeskunde (Departement)
Lid
Vanaf1 aug 2014 → 31 jul 2017 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf27 aug 2013 → 27 jun 2019 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf19 aug 2009 → 27 jun 2013
Publicaties
1 - 9 van 9
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma(2024)
Auteurs: Odrade Gondry, Vicky Caveliers, Catarina Xavier, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Katrien Glorieus, Jacques De Grève, Sofie Joris, Ine Luyten, et al.
Pagina's: 178-184 - Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study(2023)
Auteurs: Sofie Joris, H. Denys, Joelle Collignon, M. Rasschaert, Daphne t'Kint de Roodenbeke, Francois P Duhoux, J-L Canon, S. Tejpar, J Mebis, Lore Decoster, et al.
- PRECISION(2022)
Auteurs: J Thouvenin, C Van Marcke, Lore Decoster, Gordana Raicevic, Kevin Punie, M. Vandenbulcke, R A Salgado, E Van Valckenborgh, Bart Maes, Sofie Joris, et al.
- Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer(2022)
Auteurs: Sofie Joris, Christel Fontaine, Lore Decoster, Jacques Vanderauwera, Kris Thielemans, Wim Waelput, Jacques De Grève
Pagina's: 1433-1437 - Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program(2020)
Auteurs: Sofie Joris, Thierry Pieters, Anne Sibille, Frederique Bustin, Laurence Jacqmin, HR Kalantari, VEERLE SURMONT, Jean-Charles Goeminne, frederic Clinckart, Karin Pat, et al.
Pagina's: 796-801 - The clinical characteristics of breast cancers with a familial risk in which no BRCA1/2 mutations were found are sometimes suggestive for a genetic etiology(2019)
Auteurs: Sofie Joris, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Christel Fontaine, Maryse Bonduelle, Pauwels Ingrid, Erik Teugels, Jacques De Grève
- Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.(2019)
Auteurs: Sofie Joris, Christel Fontaine, Lore Decoster, Leen Vanacker, Denis Schallier, Jacques De Grève
Pagina's: 663-666 - Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families(2019)
Auteurs: Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, Ingrid Pauwels, Maryse Bonduelle, Sofie Joris, Christel Fontaine, Marian Vanhoeij, Sonia Van Dooren, Erik Teugels, et al.
- Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients(2016)
Auteurs: Sylvia De Brakeleer, Jacques De Grève, C Desmedt, Sofie Joris, Christos Sotiriou, M. Piccart, I Pauwels, Erik Teugels
Pagina's: 336-340